glp 1 drugs and hypothyroidism GLP-1 Genetics: How Genes Affect Appetite, Semaglutide, Tirzepatide Response GLP-1 with Hashimoto's Disease: Safety
Description
The unprecedented weight loss for an anti-obesity medication marks a new era in the treatment of obesity, and we now look forward to making Wegovy available to people living with obesity in the U.S. Novo Nordisk plans to launch the drug in the U.S
[PubMed Central ID: PMC9103952]
Bosello S, De Santis M, Lama G, et al
Michigan BCBS implemented what amounted to a near-complete removal of weight loss indication coverage, with narrow exceptions for members who could demonstrate specific comorbidities beyond obesity alone
2014;37(Suppl 1):S14S80
